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Fas ligand (FasL/CD95L) is a member of the tumour necrosis factor superfamily that triggers apoptosis following crosslinking of the
Fas receptor. Despite studies strongly implicating tumour-expressed FasL as a major inhibitor of the anti-tumour immune response,
little is known about the mechanisms that regulate FasL expression in tumours. In this study, we show that the cyclooxygenase
(COX) signalling pathway, and in particular prostaglandin E2 (PGE2), plays a role in the upregulation of FasL expression in colon
cancer. Suppression of either COX-2 or COX-1 by RNA interference in HCA-7 and HT29 colon tumour cells reduced FasL
expression at both the mRNA and protein level. Conversely, stimulation with PGE2 increased FasL expression and these cells showed
increased cytotoxicity against Fas-sensitive Jurkat T cells. Prostaglandin E2-induced FasL expression was mediated by signalling via the
EP1 receptor. Moreover, immunohistochemical analysis using serial sections of human colon adenocarcinomas revealed a strong
positive correlation between COX-2 and FasL (r¼0.722; Po0.0001) expression, and between EP1 receptor and FasL (r¼0.740;
Po0.0001) expression, in the tumour cells. Thus, these findings indicate that PGE2 positively regulates FasL expression in colon
tumour cells, adding another pro-neoplastic activity to PGE2.
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Colorectal cancer is a formidable health-care problem, being one
of the leading causes of cancer death worldwide. Despite evidence
that the host immune system can initiate an immune response
against colon tumours, a large number of tumours continue to
grow and evade immune-mediated elimination owing to the
development of multiple immune escape mechanisms (Waldner
et al, 2006). Upregulation of Fas ligand (FasL/CD95L) expression
by tumour cells may represent one such mechanism (O’Connell
et al, 1996). FasL is a member of the tumour necrosis factor (TNF)
superfamily that can trigger apoptotic cell death following ligation
to its receptor Fas (CD95/APO-1) on sensitive cells (Nagata and
Golstein, 1995). Many human cancers, including colon cancer,
express FasL, with growing evidence supporting a role for FasL in
colon carcinogenesis (Houston and O’Connell, 2004; Whiteside,
2007). Upregulation of FasL expression is an early event in colon
carcinogenesis (Bennett et al, 2001; Belluco et al, 2002), with
tumour-expressed FasL being associated with apoptosis and loss of
tumour-infiltrating lymphocytes (TIL) in vivo, and triggering the
death of Fas-bearing sensitive cells in vitro (O’Connell et al, 1996;
Okada et al, 2000). Engagement of Fas by FasL can also trigger
proliferation of tumour cells (Lambert et al, 2003; Li et al, 2008)
and increase tumour cell motility and invasiveness (Barnhart et al,
2004). Moreover, downregulation of FasL expression in colon
tumour cells was recently shown to result in reduced tumour
development and growth in immune-competent mice in vivo
(Ryan et al, 2005). However, despite this, little is known about the
molecular mechanisms underlying FasL expression in tumours.
Numerous studies have shown that cyclooxygenase-2 (COX-2)
plays an important role in colon carcinogenesis (Cao and Prescott,
2002). Cyclooxygenase is a rate-limiting enzyme in the conversion
of arachidonic acid to prostaglandins. Two isoforms of COX have
been characterised, COX-1 and COX-2 (Williams and DuBois,
1996). Cyclooxygenase-1 is constitutively expressed, generating
prostaglandins for normal physiological processes. In contrast,
COX-2 is usually undetectable in most normal tissues, but can be
induced rapidly by a variety of agents, including LPS, cytokines,
growth factors and tumour promoters. Overproduction of COX-2
and its major metabolite prostaglandin E2 (PGE2) has been found
in many human cancers, including colorectal tumours (Rigas et al,
1993; Eberhart et al, 1994; Sano et al, 1995), with COX-2 levels
increased in about 90% of colon cancers and B50% of pre-
malignant colorectal adenomas (Eberhart et al, 1994).
As increased expression of COX-2 and FasL in colon tumours
has been widely observed, we tested the hypothesis that the COX
signalling pathway may play a role in FasL expression in colon
tumours. Here we provide evidence that the COX signalling
pathway, and in particular PGE2, increases FasL expression in
colon tumour cells. We also show that PGE2-induced FasL
expression is mediated by the EP1 receptor. Consistent with these
findings, we observed a strong positive correlation between COX-2
expression and FasL, and between EP1 receptor expression and
FasL in human colon tumour cells in vivo. Collectively, these
results support a role for PGE2 as a critical mediator of FasL
expression in colon tumours.
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Reagents
Prostaglandin E2, SC19220 and arachidonic acid were obtained from
Cayman Chemical Company (Ann Arbor, MI, USA). SC-560 and SC-
791 were purchased from Calbiochem (San Diego, CA, USA).
rhFas:Fc was obtained from Alexis Corp. (Lausen, Switzerland).
Cell lines and culture conditions
HT29 human colon adenocarcinoma cells and Jurkat T cells were
obtained from the ATCC (Rockville, MD, USA). HCA-7 cells were a
generous gift from Susan Kirkland (University of London). WIDR,
SW480 and Caco-2 cells were obtained from Ken Nally (University
College Cork). HT29, WIDR, SW480, Caco-2 and HCA-7 cells were
maintained in DMEM containing 10% fetal calf serum (FCS)
and penicillin–streptomycin, whereas Jurkat T cells were cultured
in RPMI-1640 supplemented with 10% FCS and penicillin–
streptomycin.
RNA interference
The targeted sequences that effectively mediate the silencing
of COX-1 (siGENOME SMARTpool, M-004556-00), COX-2
(siGENOME SMARTpool, M-004557-01), EP1 (ON-TARGETplus
SMARTpool, L-005711-00), EP2 (ON-TARGETplus SMARTpool,
L-005712-00) and EP4 (ON-TARGETplus SMARTpool, L-005714-00)
expression were obtained from Dharmacon Research (Lafayette,
CO, USA). HCA-7 and HT29 cells were seeded 24h before trans-
fection at a concentration achieving 70% confluence at the time
of transfection. The transfection was carried out in serum-free
medium using Dharmafect 4 transfection reagent (Dharmacon
Research). Cells were transfected with 100nM of COX-1 small
interfering RNA (siRNA), COX-2 siRNA, EP1 siRNA, EP2 siRNA,
EP4 siRNA or irrelevant control siRNA according to the manu-
facturer’s protocol. At 48h after transfection, cells were treated
with PGE2 for 24h. Depletion of protein was confirmed by real-
time RT-PCR and immunoblotting. Culture medium was collected
and stored at  201C for subsequent measurement of PGE2 levels
by ELISA. Levels of FasL in cell lysates were determined by real-
time RT-PCR and immunoblotting.
Western blot analysis
Cells were seeded at 5 10
5 cells per well in six-well plates and
serum-deprived for 48h before treatment for 24h with either
serum-free medium containing vehicle or PGE2, unless otherwise
stated. For inhibitor studies, cells were pretreated for 1h with the
inhibitor, before the addition of PGE2. Cells were washed in PBS
and lysed on ice in 50mM Tris-HCl, pH 8, containing 150mM NaCl
and 1% Triton X-100, supplemented with the complete-TM
mixture of protease inhibitors (Roche Molecular Biochemicals,
Indianapolis, IN, USA). Protein concentrations were measured
using the BCA Protein assay (Pierce, Rockford, IL, USA). Proteins
(40mg protein per lane) were separated on a 10% SDS–poly-
acrylamide gel, transferred to a nitrocellulose membrane and then
probed with one of the following primary antibodies: anti-FasL
(N-20/1:200 dilution), anti-Fas (C-20/1:1000), anti-COX-1
(C-20/1:250) (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
anti-FasL (Ab-1/1:100 dilution) (Calbiochem), anti-TNF-related
apoptosis-inducing ligand (anti-TRAIL; 1:500 dilution), anti-
COX-2 (1:1000), anti-EP1 (1:300), anti-EP2 (1:500), anti-EP4
(1:500) (Cayman Chemical Company). As an internal control, all
membranes were subsequently stripped of the first antibody and
reprobed with anti-b-actin-specific antibody (AC-74; 1:10000
dilution; Sigma, St Louis, MO, USA). The antigen–antibody
complex was detected by incubating the membranes for 1h at
room temperature with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody (Dako Corp., Carpinteria,
CA, USA). Peroxidase activity was detected with the enhanced
chemiluminescence system (Pierce) and analysed using Scion Image
analysis software (Scion Inc., Frederick, MD, USA). Changes in
protein expression were determined after normalising the band
intensity of each lane to that of b-actin.
Quantification of mRNA
Total RNA was isolated from cultured cells using the Agilent Total
RNA isolation kit (Agilent Technologies, Santa Clara, CA, USA)
according to the manufacturer’s instructions and cDNA synthe-
sised using AMV reverse transcriptase, random hexanucleotide
primers, RNasin (40U) and dNTPs (500mM) (Promega, Madison,
WI, USA). Quantitative PCR was then performed in triplicate using
an ABI PRISM 7500 Sequence Detection System and commercially
available TaqMan probes (Applied Biosystems, Foster City, CA,
USA). Briefly, cDNA in 22.5ml of water was mixed with 2.5mlo f
20  TaqMan Gene Expression assay primer and probe mix
(FasL¼Hs00181225, TRAIL¼Hs00366272, EP1¼Hs00168752,
EP2¼Hs00168754, EP3¼Hs00168755, EP4¼Hs00168761, glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)¼4326317E) and
25mlo f2   TaqMan Gene Expression master mix in a 96-well
optical reaction plate. The following PCR conditions were used:
501Cf o r2m i n ,t h e n9 5 1C for 10min, followed by 50 cycles at 951C
for 15s and 601C for 1min. The expression level of the target genes
was normalised to internal GAPDH. Data were analysed using
Microsoft Excel and calculated using the relative standard curve
method (ABI, User Bulletin 2).
Prostaglandin E2 assay
Prostaglandin E2 production was measured by ELISA, according to the
manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA).
Co-culture experiment
HCA-7 and HT29 cells were plated in triplicate in 96-well plates
and allowed to reach B70% confluency. Cells were serum-starved
for 48h, followed by treatment with serum-free medium contain-
ing vehicle (0.1% DMSO), 0.5 or 1.0mM PGE2 for 24h. Cells were
then fixed with 1.5% paraformaldehyde and washed with PBS.
Jurkat cells were added at a concentration of 5 10
4 cells per well.
To block FasL-mediated cytotoxicity, Jurkat cells were co-cultured
with paraformaldehyde-fixed 1.0mM PGE2-treated cells in the
presence of recombinant Fas:Fc (10mgml
 1). After 24h, Jurkat
cell viability was assessed by measuring the increase in fluores-
cence intensity associated with the cellular reduction of resazurin
to resorufin, according to the manufacturer’s instructions (R&D
Systems). Briefly, the cells were pulsed with 44mM resazurin
solution and 1h later fluorescence was measured at 535/590nm
using a standard spectrophotometer in bottom reading mode.
This fluorescence was expressed as a percentage of that shown
by control Jurkat T cells in RPMI-1640 only, after subtraction
of background fluorescence.
Immunofluorescent detection of FasL
Cells were seeded at 2 10
5 cells per well in six-well plates
containing sterile coverslips. After serum-starving for 48h, cells
were treated with serum-free medium containing 0.5, 1.0 or 2mM
PGE2 for 24h. Cells were fixed with 1.5% paraformaldehyde,
permeabilised with 0.2% Triton X-100 in PBS and nonspecific
binding of antibody was blocked with 10% normal goat serum for
30min at room temperature. Cells were incubated overnight at 41C
with anti-FasL-specific antibody (G247-4; Pharmingen, San Diego,
CA, USA) diluted 1:50. Antibody binding was localised using an
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Figure 1 Prostaglandin E2 induces FasL expression in colon cancer cells. (A) HCA-7 cells and HT29 cells were cultured in serum-free medium for 48h
before treatment with PGE2. After 24h, total RNA was extracted and was reverse transcribed to cDNA. FasL mRNA levels were measured by quantitative
real-time RT-PCR. Columns indicate fold induction relative to control (DMSO). Mean±s.e.m. values are plotted. (B) Following the isolation of total cellular
protein from cells treated as in (A), equal amounts of protein were separated by SDS–PAGE and visualised with anti-FasL (N-20), anti-FasL
D (Ab-1), anti-
Fas or anti-b-actin. Semiquantitative analysis of FasL expression was determined by calculating the ratio between FasL protein and b-actin protein from three
independent experiments. Mean±s.e.m. values are plotted (*Po0.05, **Po0.01; compared with DMSO control; Student’s t-test). (C) Cells were treated
as in (A) and FasL protein was detected by immunofluorescence. (D) HCA-7 cells were serum-starved for 48h and thereafter the medium was replaced
with complete medium (10% serum) for 24h. As a control for FasL detection, Jurkat T cells were treated with 2.5mgml
 1 PHA for 24h, which has been
shown to increase FasL expression in these cells. Cellular lysates were analysed by Western blotting using antibodies against FasL and b-actin. (E) HCA-7
cells were cultured in complete medium followed by treatment with PGE2 for 24h. Cellular isolates were treated as in (D).
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sFITC-labelled secondary antibody (Dako Corp.). Coverslips were
mounted on slides with anti-fading mounting media (Dako Corp.)
and visualised using a fluorescent microscope when dry.
Human colon adenocarcinoma tissues and
immunohistochemistry
Formalin-fixed, paraffin-embedded human colonic adenocarcino-
mas (n¼27) were obtained from the archives of the Mercy Hospital,
Cork, following a protocol approved by the Cork Teaching Hospitals
Clinical Research Ethics Committee. None of the cases used in this
study had patient identifiers and strict confidentiality was main-
tained. None of the patients had received chemotherapy, radio-
therapy or immunotherapy before tissue collection.
Tissue sections were de-paraffinised in xylene and rehydrated
before analysis. Antigen retrieval was performed by microwave
irradiation in 0.01 M citrate buffer, pH 6.0. Slides were washed and
endogenous peroxidase was quenched with 3.0% hydrogen
peroxide in methanol for 5min. Nonspecific binding was blocked
with 5% normal serum in wash buffer for 1h. Serial sections were
incubated overnight at 41C with monoclonal FasL (G247-4)
antibody (Pharmingen) at 5mgml
 1, rabbit polyclonal COX-2 anti-
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Figure 2 Suppression of either COX-1 or COX-2 by RNAi reduces FasL expression in HT29 and HCA-7 colon cancer cells. (A) HCA-7 and HT29 cells
were transfected with control nonspecific RNAi (siCONT), COX-2-specific RNAi (siCOX-2) or COX-1-specific RNAi (siCOX-1). After 48h, cell culture
medium and cellular lysates were collected. Levels of PGE2 in the cell culture medium were determined by ELISA. Mean±s.e.m. values are plotted. Changes
in COX-1 and COX-2 protein levels were detected by Western blotting. (B) RNA was extracted from cells treated as in (A) and reverse transcribed to
cDNA. FasL mRNA levels were measured by quantitative real-time RT-PCR. Columns indicate fold induction relative to siCONT-treated cells. Mean±s.e.m.
values are plotted. Cellular lysates were analysed by Western blotting using antibodies raised against FasL, TRAIL, Fas or b-actin.
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sbody (Santa Cruz Biotechnology) at 0.5mgml
 1, rabbit polyclonal
EP1 antibody (Cayman Chemical Company) at 0.27mgml
 1 or goat
polyclonal COX-1 antibody (Santa Cruz Biotechnology) at
0.133mgml
 1. Antibody binding was localised using a biotinylated
secondary antibody, avidin-conjugated HRP and DAB substrate,
contained within the Vectastain ABC detection kit (Vector
Laboratories, Burlingame, CA, USA). Slides were counterstained
with haematoxylin and mounted. Parallel negative controls were
performed for each antibody, using rabbit (COX-2, EP1) IgG,
mouse (FasL) IgG or normal goat serum (COX-1) instead of
primary antibody.
Neoplasms displaying immunoreactivity in more than 5%
of the tumour cells were regarded as positive. Semiquantitative
analysis of the immunohistochemical score for COX-2, COX-1,
EP1 and FasL staining was performed by light microscopy for
each tumour using a scoring system that included the
extent (0¼negative; 0.25¼1–25% of cells stained; 0.5¼26–50%
of cells stained; 0.75¼51–75%; 1¼475% of cells stained)
and intensity (0, negative; 1, weak; 2, moderate; 3, strong; 4,
intense) of staining. The scores from the two scales were
multiplied by each other to give a single immunohisto-
chemical score. For each tumour, 10 random high-power fields
were scored.
Statistics
All experiments were performed in triplicate unless otherwise
indicated, and mean values were presented as mean±s.e.m. Paired
Student’s t-test was performed to compare the data between
indicated groups. Spearman’s rank correlation test was used for
correlation between the expression of FasL and COX-1, COX-2 and
EP1 in colon tumour tissue. A value of Po0.05 was considered
statistically significant.
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Figure 3 Inhibition of COX-1 using SC-560 or that of COX-2 using SC-791 reduces FasL expression in colon cancer cells. (A) HCA-7 and HT29 cells
were serum-deprived for 48h before treatment with SC-560 or SC-791. After 1h, cell culture medium was collected and the levels of PGE2 were
determined by ELISA. Mean±s.e.m. values are plotted. (B) HCA-7 and HT29 cells were serum-deprived for 48h, treated with SC-560 or SC-791 and 24h
later cell lysates were collected. Lysates were analysed by Western blotting using antibodies raised against FasL and b-actin. Data shown are representative of
three independent experiments. (C) HCA-7 cells were serum-deprived for 48h, treated with 10mM SC-560 and/or 10mM SC-791 and 24h later cell lysates
were collected and treated as in (B).
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Prostaglandin E2 induces FasL mRNA and protein
expression in colon cancer cells
Numerous studies have shown that PGE2 produced via the COX-2
signalling pathway plays a crucial role in the development of colon
cancer (Kamei et al, 2003). To determine if PGE2 induces FasL
expression in colon cancer cells, we analysed the effect of PGE2 on
FasL expression in HCA-7 human colon cancer cells. HCA-7 cells
have high endogenous levels of COX-2, PGE2 and FasL. As COX-2
is an inducible gene that is regulated by, among other factors,
serum (Dubois et al, 1998), HCA-7 cells were serum-starved before
treatment with increasing concentrations of PGE2, ranging from
low (0.025mM) to high (10mM), and FasL expression was analysed
by real-time RT-PCR, Western blotting and immunofluorescence.
As shown in Figure 1, PGE2 increased FasL expression at both the
mRNA and protein level, with maximum induction of FasL mRNA
occurring at 1.0mM PGE2 (42.7-fold induction) (Figure 1A).
Analysis of protein production by Western blotting and immuno-
fluorescence showed that FasL protein also peaked at relatively low
levels of PGE2 (0.5–1.0mM) (Figure 1B and C), whereas the levels of
the Fas receptor were unaffected. This increase in FasL protein was
confirmed using two different anti-FasL-specific antibodies.
Prostaglandin E2 engagement also increased FasL expression in
HT29 colon cancer cells. Relative to HCA-7 cells, HT29 cells have
low levels of COX-2 and PGE2. However, there was an B5.7- and 3.6-
fold induction in FasL mRNA following incubation with 0.5 and
1.0mM PGE2, respectively (Figure 1A), with FasL protein also peaking
at 0.5–1.0mM PGE2 (Figure 1B and C). Based on these findings, a
concentration of 1.0mM PGE2 was used in all subsequent experiments.
Since serum deprivation induces cell cycle arrest, and FasL
expression in T cells has been reported to be cell cycle sensitive, we
also determined if PGE2 induced FasL expression in cells grown in
complete medium (10% serum). The addition of serum to serum-
starved cells increased FasL expression in these cells by B40% as
assessed by Western blotting (Figure 1D). However, the addition of
serum also induced an increase in PGE2 secretion by these cells
(data not shown). Thus, we investigated if PGE2 induces FasL
expression in cells grown in complete medium. The addition of
PGE2 increased FasL expression in HCA-7 cells and this increase
was B2.5 times (1mM PGE2) greater than that induced by serum
alone (Figure 1E), suggesting that PGE2 induces FasL expression
independently of entry into the cell cycle. Interestingly, this
induction of FasL by PGE2 also exhibited a ‘bell-shaped’ dose–
response relationship, similar to that obtained following PGE2
treatment of serum-starved cells. This ‘bell-shaped’ dose–response
relationship has been previously demonstrated in SW1116 cells on
measuring proliferation in response to PGE2 and was suggested to
be due to differential activation of the EP receptors at different
concentrations of PGE2 (Qiao et al, 1995). Prostaglandin E2 binds to
and activates four different receptor subtypes, EP1, EP2, EP3 and
EP4 (Bos et al, 2004), suggesting that one (or more) EP receptor is
involved in inducing FasL expression in colon cancer cells.
Furthermore, depletion of COX-1 and COX-2 by RNA inter-
ference (RNAi) reduced FasL expression in both HCA-7 and HT29
cells. Although COX-2 is the isoform that is overexpressed in colon
cancer, evidence from mouse experiments has also implicated
COX-1 as a causal agent in COX-induced colorectal carcinogenesis
(Chulada et al, 2000), with production of PGE2 being the common
denominator. Thus, the expression of both COX-1 and COX-2 was
reduced by RNAi, and the efficiency of depletion was verified
by PGE2 ELISA and Western blotting (Figure 2A). Suppression
of COX-2 and COX-1 by RNAi reduced FasL expression in both
HCA-7 and HT29 cells, as evidenced by a reduction in FasL mRNA
and protein production (Figure 2B). Cyclooxygenase-2 depletion
resulted in a 455% reduction in FasL mRNA in HCA-7 cells and a
430% reduction in FasL mRNA in HT29 cells, as assessed by real-
time RT-PCR, whereas FasL mRNA was reduced by 438 and 432%
in HCA-7 and HT29 cells, respectively, by COX-1 RNAi. Western
blot analysis confirmed these findings at the protein level, with
siCOX-2 and siCOX-1 significantly reducing FasL protein in HCA-7
(Po0.01 and Po0.01, respectively) and HT29 (Po0.01 and Po0.05,
respectively) cells, as assessed by semiquantitative densitometric
analysis. This effect was specific for FasL and did not affect TRAIL,
another death-inducing member of the TNF superfamily, or Fas
receptor, as assessed by real-time RT-PCR (data not shown) and
Western blotting (Figure 2B). Importantly, PGE2 restored FasL
production in both cell lines in the presence of COX-2 and COX-1
RNAi, demonstrating that COX-derived PGE2 is an important
mediator of FasL expression in colon cancer cells. These findings
were also confirmed using COX-1- and COX-2-specific inhibitors.
As shown in Figure 3, treatment with SC-560 (COX-1-specific
inhibitor) or SC-791 (COX-2-specific inhibitor) reduced PGE2
secretion into the culture medium in both systems, with a
concomitant reduction in FasL protein. Interestingly, inhibition of
both COX-1 and COX-2 did not completely abrogate FasL
expression (Figure 3C), suggesting that in colon tumour cells
PGE2 is only one of the factors responsible for regulating FasL
expression.
To corroborate the role of PGE2 in inducing FasL expression at a
functional level, HCA-7 and HT29 cells were treated with PGE2 for
24h, washed with PBS, fixed and then co-cultured with Jurkat
T cells. The Jurkat T-cell line is a Fas-sensitive cell line of T-cell
origin that is widely used experimentally as a model for activated
T cells. There was a 14.5 and 29.1% reduction in Jurkat T-cell
viability following co-culture with control HT29 and HCA-7 cells,
respectively. However, upregulation of FasL expression by PGE2 on
HCA-7 and HT29 cells substantially increased their effector
function against the Jurkat T cells (Figure 4). Following co-culture
with 1.0mM PGE2-treated HT29 and HCA-7 colon cancer cells,
HT29 HCA-7
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Figure 4 Reduction in Jurkat T-cell viability following co-culture with
colon cancer cells treated with PGE2. HT29 and HCA-7 cells were serum-
deprived for 48h, followed by treatment for 24h with 0.1% DMSO, 0.5 or
1.0mM PGE2. Cells were fixed and then co-cultured with Jurkat T cells for
24h. Jurkat T-cell viability was determined by resazurin reduction. To block
FasL-mediated apoptosis, Jurkat T cells were also co-cultured with 1.0mM
PGE2-treated colon cancer cells in the presence of 10mgml
 1 recombinant
Fas:Fc blocking protein. Data denote mean±s.e.m. and are representative
of two independent experiments. Viability is expressed as an index (% of
control Jurkat T cells maintained in medium only).
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sJurkat T-cell viability decreased by 55.9 and 54.8%, respectively,
relative to cells cultured in medium only. This reduction in cell
viability following co-culture with 1.0mM PGE2-treated cells was
confirmed to be Fas-mediated, as it could be blocked by the
addition of neutralising anti-FasL antibody.
Prostaglandin E2-induced FasL expression is EP1
receptor-dependent
Prostaglandin E2 exerts its biological activity through four
different receptor subtypes, EP1, EP2, EP3 and EP4 (Bos et al,
2004), with HCA-7 cells expressing all four receptors, as deter-
mined by real-time RT–PCR. In contrast, HT29 cells expressed
only EP1 and EP4. As EP1, EP2 and EP4 have previously been
reported to play a role in colon carcinogenesis, we investigated
whether these receptors are involved in PGE2-induced FasL
expression. In the first experiment, we utilised siRNA to down-
regulate EP1, EP2 and EP4 in HCA-7 cells. Transfection with EP1-,
EP2- and EP4-specific siRNA resulted in efficient impairment of
EP1, EP2 and EP4 transcription (64, 84 and 59% reduction in
mRNA, respectively) and protein translation (Figure 5A).
Cells were then treated with PGE2 and FasL production was
analysed by real-time RT-PCR and immunoblotting. As shown in
Figure 5B and C, suppression of EP1 prevented PGE2-induced FasL
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Figure 5 Suppression of EP1 blocks PGE2-induced FasL upregulation in HCA-7 and HT29 cells. (A) HCA-7 cells were transfected with control
nonspecific RNAi (siCONT), EP1-specific RNAi (siEP1), EP2-specific RNAi (siEP2) or EP4-specific RNAi (siEP4). After 48h, cells were lysed and successful
depletion of EP1, EP2 and EP4 receptors in cells transfected with the corresponding siRNA was confirmed by Western blotting. (B) At 48h after
transfection with siCONT, siEP1, siEP2 or siEP4, HCA-7 and HT29 cells were treated with 1.0mM PGE2 for 24h and RNA was extracted and reverse
transcribed to cDNA. FasL mRNA levels were measured by quantitative real-time RT-PCR. Columns denote fold induction relative to siCONT-treated cells.
Mean±s.e.m. values are plotted. (C) Total protein was isolated from cells treated as in (B) and lysates were analysed by Western blotting using antibodies
raised against FasL and b-actin. (D) Cells were serum-starved for 48h, pretreated with SC19220 for 1h, followed by treatment with 1.0mM PGE2 for 24h.
Cells were lysed and analysed by Western blotting using antibodies raised against FasL and b-actin.
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sexpression in HCA-7 cells at both the mRNA and protein levels. In
contrast, EP2- and EP4-specific siRNA had little or no effect.
Similar results were obtained with HT29 cells, where transfection
with EP1-specific siRNA resulted in a decreased induction of FasL
following treatment with PGE2 (Figure 5B and C).
As an alternative approach to inhibiting EP1 receptor activity, in
a second experiment cells were pretreated for 1h with SC19220
(25–100mM), which is an EP1 receptor antagonist, before the
addition of PGE2 and FasL expression was analysed by
immunoblotting. As shown in Figure 5D, SC19220 prevented the
PGE2-induced increase in FasL expression in a dose-dependent
manner, consistent with a role for EP1 receptor in mediating
this effect.
To determine if there was any correlation between the basal
expression level of FasL and the EP1 receptor, five different colon
cancer cell lines were grown in complete media and the expression
of COX-1, COX-2, FasL and EP1 was assessed by Western blotting
(Figure 6A), whereas PGE2 secretion was determined by ELISA
(Figure 6B). Four of the cell lines (HT29, HCA-7, WIDR and
Caco-2) expressed all five proteins, although at very different levels.
(COX-2 was detectable in WIDR cells on increased exposure). In
contrast, SW480 cells were negative for COX-2, whereas
Caco-2 cells expressed very low levels of EP1 receptor. Interestingly,
although both HCA-7 and Caco-2 cells strongly expressed
COX-2 and PGE2, HCA-7 cells exhibited much stronger
expression of FasL than Caco-2 cells, which is likely due to the
much higher expression level of EP1 receptor found in these cells.
HT29 cells also strongly expressed FasL, despite producing much
lower levels of PGE2. However, HT29 cells also strongly expressed
the EP1 receptor. SW480 and WIDR in turn secreted very low
amounts of PGE2. However, SW480 cells expressed more EP1
receptor than WIDR cells, together with stronger basal production
of FasL. Finally, 1.0mM PGE2 induced FasL expression in both
SW480 and WIDR cells, but not in Caco-2 cells, which is likely
due to the very low/negligible levels of EP1 receptor expressed by
Caco-2 cells.
Correlation between COX-1, COX-2, EP1 receptor and FasL
expression in human colon cancer cells
To determine if our in vitro data had in vivo relevance, COX-1,
COX-2, EP1 receptor and FasL expression was analysed by
immunohistochemistry on sequential sections from 27 human
colon cancer tissues. Examination of stained tumour specimens
revealed that 81% (22 out of 27) of the tumours expressed FasL and
96% (26 out of 27) expressed EP1, whereas COX-1 protein was
detected in the neoplastic cells of 88% (22 out of 25) of tumours
and COX-2 in 85% (23 out of 27) of tumours. Staining for all four
proteins varied in intensity and extent both within individual
tumours and between tumours, with some cells in the stromal
compartments also exhibiting positive immunoreactivity. How-
ever, strong immunostaining for FasL was seen more frequently in
cancer cells with strong immunostaining for COX-2 (Figure 7A)
and EP1 receptor (Figure 7C). In contrast, strong immunostaining
for COX-1 did not frequently coincide with strong FasL
immunostaining (Figure 7B). No staining was seen when the
primary antibody was substituted with isotype-matched controls
(rabbit and mouse) or non-immune serum goat (Figure 7D).
To determine if expression of the proteins correlated in vivo,
consecutive sections were scored in a blinded fashion for both the
number of COX-1-, COX-2-, EP1- and FasL-positive tumour cells
and the intensity of staining, and the final scores were multiplied
to give a total immunohistochemical score. There was no
correlation between the immunostaining scores of COX-1 and
FasL. However, a strong positive correlation was observed between
COX-2 and FasL (r¼0.722; Po0.0001), and between EP1 and FasL
(r¼0.740; Po0.0001) immunostaining, indicating a possible
interrelationship in the expression of these proteins.
DISCUSSION
Although there are conflicting reports on the role of FasL in
tumorigenesis (Restifo, 2000;, O’Connell et al, 2001), considerable
evidence now exists indicating that FasL expression by tumour
cells may aid in tumour development. Studies performed in vitro,
as well as evidence from numerous in situ examinations, indicate
that tumour-expressed FasL is associated with apoptosis of TIL
and may thus protect tumour cells from destruction by the
immune system (O’Connell et al, 2001; Whiteside, 2007). Tumour-
expressed FasL has also been shown to be associated with
metastasis of tumour cells to the lymph nodes and liver (Mann
et al, 1999; Younes et al, 2000), whereas ligation of Fas by FasL can
stimulate cell proliferation (Lambert et al, 2003; Li et al, 2008), and
increase tumour cell motility and invasiveness (Barnhart et al,
2004; Peter et al, 2007). Furthermore, recent studies suggest that
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Figure 6 FasL expression is correlated with EP1 receptor expression in
colon cancer cells in vitro.( A) Cells were seeded at 1 10
5 cells per ml and
after 24h the medium was replaced with fresh growth medium. After 24h,
cell culture medium and cellular lysates were collected. Cellular lysates
were analysed by Western blotting using antibodies raised against COX-1,
COX-2, FasL, EP1 receptor or b-actin. (B) Levels of PGE2 in the cell culture
medium were determined by ELISA. Mean±s.e.m. values are plotted. (C)
SW480, WIDR and Caco-2 cells were serum-starved for 48h before
treatment with 1.0mM PGE2 for 24h. Cellular isolates were separated by
SDS–PAGE and visualised with anti-FasL or anti-b-actin.
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stumour-expressed FasL may contribute to tumour growth in
cancers associated with inflammation, in part through the
induction of chemotactic factors (Matsumoto et al, 2007).
Together, these findings suggest that the FasL signalling pathway
plays a critical role in tumour development and immune evasion,
and that suppression of FasL expression may aid in the treatment
of certain cancers. In support of this, we have recently shown that
specific inhibition of FasL expression in colon cancer cells
significantly retards tumour formation in immune-competent
syngeneic mice (Ryan et al, 2005). However, despite the role of
FasL in tumorigenesis, little is known about the regulation of this
molecule in tumour cells.
Increased PGE2 production has been shown to be strongly
associated with colorectal neoplasia, increasing critical pro-
survival and anti-apoptotic factors that favour cell growth (Wang
and Dubois, 2006). However, the effector genes downstream of
PGE2 have not been well characterised. In this study, we show
using a variety of methods that PGE2 regulates FasL expression in
colon cancer cells, suggesting that PGE2 may also play a role in
FasL-mediated tumour immune evasion. Induction of FasL in vitro
occurred at relatively low concentrations of PGE2 (B0.5–1.0mM),
with both COX-2 and COX-1 appearing to play a role in this
process. However, in human colon cancer cells in vivo, COX-2
appears to play a more important role in the induction of FasL
than COX-1, with expression of COX-2 and not COX-1 correlating
with FasL expression. One potential explanation may be that
although both isoforms may play a role in the induction of FasL
expression through production of PGE2, in vivo COX-2 is the
isoform that is increased in colon cancer, with a concomitant
increase in PGE2 (Rigas et al, 1993; Eberhart et al, 1994). In
contrast, COX-1 expression has been reported to remain constant
under most physiological and pathological conditions (Eberhart
et al, 1994; Sano et al, 1995). Although recent studies have shown
that COX-1 may also play a role in carcinogenesis in some cancers,
such as ovarian (Gupta et al, 2003), head and neck (Erovic et al,
2008) and colon cancer (Chulada et al, 2000), the common
denominator in all these studies is an increase in the overall level
of PGE2. Following upregulation during colon carcinogenesis,
COX-2 may be the primary source of PGE2 in the tumour
microenvironment, and thus may play a more important role in
inducing FasL expression in human colon tumour cells in vivo.
Prostaglandin E2 mediates its effects by binding to and
activating four different G-protein-coupled receptors, EP1, EP2,
EP3 and EP4, with genetic deletion and pharmacologic manipula-
tion of the EP receptors identifying different roles for EP1, EP2 and
EP4 in intestinal tumorigenesis (Wang and Dubois, 2006). In the
current study, we show that the EP1 signalling pathway is the
predominant pathway that mediates PGE2-induced FasL expres-
sion. Prostaglandin E2-induced FasL was blocked by both EP1-
specific RNAi and pharmacologic inhibition of EP1, but not by
FasL COX-2
FasL EP1
FasL COX-1
Goat (–)
Mouse(–)
Rabbit (–)
Figure 7 Immunohistochemical visualisation of COX-1, COX-2, EP1 receptor and FasL in human colon cancer. (A) Cyclooxygenase-2 and FasL, (B)
COX-1 and FasL and (C) EP1 receptor and FasL immunostaining in cancer cells, with the upper and lower panels representing different colon cancer
specimens. Specific protein stained brown. (D) Rabbit, goat and mouse controls demonstrated no staining. Representative micrographs are shown. Original
magnification:  300.
PGE2 upregulates FasL in colon cancer cells
G O’Callaghan et al
510
British Journal of Cancer (2008) 99(3), 502–512 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sEP2- or EP4-specific RNAi. Moreover, a strong correlation was
observed between EP1 and FasL expression in colon cancer cells
in vitro and in vivo, indicating a possible interrelationship in the
expression of these two proteins and together suggesting that these
findings may have physiological relevance. The EP1 receptor has
previously been shown to play an important role in colon
carcinogenesis. The development of both aberrant crypt foci and
colon tumours was significantly reduced in EP1-knockout mice
following treatment with the colon carcinogen azoxymethane
(Watanabe et al, 1999; Kawamori et al, 2005). Also recent studies
characterising EP receptor expression in a variety of tumour types
showed that expression of EP1 is increased in tumour cells relative
to normal tissue (Shoji et al, 2004; Miyata et al, 2006; Rask et al,
2006) and is associated with tumour progression and metastasis in
prostate cancer (Miyata et al, 2006). Similarly, FasL expression has
been shown to be upregulated in tumour cells relative to normal
tissue and is associated with tumour progression and metastasis
(Mann et al, 1999; Osaki et al, 2001; Belluco et al, 2002). As
inhibition of FasL expression in colon cancer cells significantly
retards tumour formation in mice (Ryan et al, 2005), these findings
suggest that targeting the EP1 receptor may help to prevent or treat
colon cancer, in part through preventing FasL upregulation in
tumour cells.
However, PGE2 has also been shown to downregulate FasL
expression in T cells, inhibiting activation-induced cell death
(Porter and Malek, 1999). In contrast, FasL expression has recently
been shown to be induced in normal colonocytes by PGE2 (Kim
et al, 2007). Our results clearly demonstrate that PGE2 induces
FasL expression in colon tumour cells. Together, these findings
suggest that PGE2 can have multiple effects, perhaps depending on
the cell type and oncogenic state of the target cell. Interestingly, in
agreement with our findings, the EP1 receptor also played a critical
role in PGE2-mediated induction of FasL in normal colonocytes.
Although in this model upregulation of FasL expression resulted
in colonocyte apoptosis, tumour cells have previously been shown
to exhibit enhanced resistance to Fas-mediated apoptosis
(Oikonomou et al, 2007). Thus, upregulation of FasL expression
in response to PGE2 and subsequent activation of the EP1 receptor,
coupled with resistance to Fas-mediated apoptosis, may aid in
tumour development. Furthermore, activation of the transcription
factor NF-kB was critical for FasL expression in toxin A-exposed
colonocytes. Future studies will determine if EP1-mediated
activation of NF-kB also plays an important role in inducing FasL
expression in colon tumour cells.
In summary, our findings demonstrate that PGE2 upregulates
FasL expression in colon cancer cells through the EP1 receptor.
Interruption of the PGE2 pathway in vivo has been shown to delay
and/or prevent tumour progression in many systems. These anti-
tumour effects have been attributed to various mechanisms, such
as reduced angiogenesis and increased apoptosis. Our finding that
the pro-inflammatory cytokine PGE2 upregulates FasL expression
in colon cancer cells adds another pro-neoplastic activity to this
pathway, that is, tumour immune evasion, and suggests that
targeting the PGE2–EP1–FasL signalling pathway may aid in the
development of new therapeutic strategies to both prevent and
treat this malignant disease.
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